BRADFORD PATRICIA A purchased $7K of PHIO
BRADFORD PATRICIA A purchased 6,500 shares of Phio Pharmaceuticals Corp. (PHIO) at $1.01 on 2026-09-24.
How this was made
The 30-second read
Why it matters
The filing provides the first public record of a director's purchase, offering a fresh data point for investors.
Market read
A director's purchase is a modest bullish signal but unlikely to move the stock significantly.
What to watch
No disclosed strategic rationale; size is modest relative to float.
Background
SEC Form 4 filing discloses insider transactions for public companies.
Ticker impact
Director Patricia Bradford bought 6,500 shares at $1.0127, raising her stake to 64,151 shares.
Potential slight upside pressure as market absorbs insider buying.
The purchase size is small relative to market cap, but director involvement may be viewed positively by investors.
Market effects
Minimal impact on biotech sector; typical insider activity.
None
None
Counterpoint
The purchase may be routine portfolio rebalancing, not a strong endorsement.
Key entities
- companyPhio Pharmaceuticals Corp.
Biotech firm listed on Nasdaq under ticker PHIO.
- personPatricia Bradford
Director of Phio Pharmaceuticals.
